Cornerstone Therapeutics (NASDAQ:CRTX) has reached a preliminary agreement to acquire acute-care hospital products company EKR Therapeutics and the rights to two of its drugs in a deal valued at up to $150 million. Under the definitive agreement, Cornerstone would pay $125 million in cash up front. The Cary, North Carolina pharmaceutical company could pay up […]
A hyponatremia treatment from Cornerstone Therapeutics (NASDAQ:CRTX) is now targeted for a regulatory approval decision in the fourth quarter. The U.S. Food and Drug Administration has accepted the new drug application for the compound CRTX 080. The agency set a goal date of a Prescription Drug User Fee Act (PDUFA) date of Oct. 29 to […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
If your pharmaceutical company sells a product or is developing a drug for use in hospitals, Cornerstone Therapeutics (NASDAQ:CRTX) CEO Craig Collard wants to talk to you. Cornerstone finished 2011 with $74 million in cash on hand. Looking ahead to 2012, the company plans to spend it on acquisitions. The pharmaceutical company has shaped its […]
Cornerstone Therapeutics (NASDAQ:CRTX) has sold rights to two anti-infective products in deals that complete the specialty pharmaceutical company’s shift away from marketing primary care drugs. Cornerstone will now focus on marketing hospital-based drugs. Cornerstone receives an an undisclosed amount of cash for divesting product rights and inventory for the antibiotic treatments Factive and Spectracef to […]
The cardiovascular drug candidate developed by Cardiokine was the centerpiece of Cornerstone Therapeutics‘ (NASDAQ:CRTX) acquisition of the drug developer announced last week. But while it’s clear Cornerstone hopes lixivaptan helps fill out its drug portfolio, regulatory approval won’t make Cornerstone the initial beneficiary. That honor belongs to a company that had nothing to do with […]
Respiratory treatments company Cornerstone Therapeutics (NASDAQ:CRTX) is broadening its offerings with the acquisition of cardiovascular drug company Cardiokine Biopharma. Cary, North Carolina-based Cornerstone’s acquisition of Cardiokine, located in Philadelphia, was completed on Dec. 30, a day after Cardiokine filed a New Drug Application (NDA) for its lead drug candidate, lixivaptan. Lixivaptan has completed phase 3 […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Cornerstone Therapeutics (NASDAQ:CRTX) is in the crosshairs of competitor ONY over a published study that concludes its respiratory drug is riskier to infants than Cornerstone’s. Privately held ONY claims damages of $10 million and is now seeking to recover them through a lawsuit that targets Cornerstone; Italian company Chiesi Farmaceutici, which licensed the drug to […]
Former Covidien (NYSE:COV) executive Kenneth McBean has joined Cornerstone Therapeutics (NASDAQ:CRTX) to become president of the respiratory therapeutics company. The hire comes as Cornerstone puts more emphasis on its branded products and transitions away from sales of unbranded drugs. As Covidien’s vice president and general manager of Specialty Pharmaceuticals from March 2009 through last May, […]
Cornerstone Therapeutics (NASDAQ:CRTX) expects its latest respiratory drug will get U.S. Food and Drug Administration approval in time for the coming cold and flu season. The Cary, North Carolina-based respiratory therapeutics company has received a response from the FDA and Cornerstone is preparing to answer the regulator’s questions. Cornerstone CEO Craig Collard assured analysts that […]
Respiratory drugs company Cornerstone Therapeutics (NASDAQ:CRTX) broke $125 million in annual revenue last year helped by the strength of its two biggest selling products, both of them acquisitions from other companies. Cornerstone is now closing in on another deal that could bring yet another product to its portfolio. Cornerstone expects to complete a deal “in […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Cornerstone Therapeutics has a new chief financial officer, bringing in an executive from Durham, North Carolina clinical research organization Quintiles. Vincent Morgus is a Quintiles veteran, having worked at the CRO for more than 16 years.